scispace - formally typeset
J

James B. Leverenz

Researcher at Lou Ruvo Brain Institute

Publications -  302
Citations -  30770

James B. Leverenz is an academic researcher from Lou Ruvo Brain Institute. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 80, co-authored 274 publications receiving 24935 citations. Previous affiliations of James B. Leverenz include University of Washington & University of North Carolina at Chapel Hill.

Papers
More filters
Journal ArticleDOI

Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium

Ian G. McKeith, +95 more
- 04 Jul 2017 - 
TL;DR: The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade.
Journal ArticleDOI

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

TL;DR: Evidence from many independent research centers strongly supports the existence of a specific disease, as defined by the presence of A&bgr; plaques and neurofibrillary tangles.
Journal ArticleDOI

Analysis of shared heritability in common disorders of the brain

Verneri Anttila, +720 more
- 22 Jun 2018 - 
TL;DR: It is demonstrated that, in the general population, the personality trait neuroticism is significantly correlated with almost every psychiatric disorder and migraine, and it is shown that both psychiatric and neurological disorders have robust correlations with cognitive and personality measures.
Journal ArticleDOI

The Parkinson Progression Marker Initiative (PPMI)

TL;DR: The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials.